2. Academic Validation
  3. Pan-serotype dengue virus inhibitor JNJ-A07 targets NS4A-2K-NS4B interaction with NS2B/NS3 and blocks replication organelle formation

Pan-serotype dengue virus inhibitor JNJ-A07 targets NS4A-2K-NS4B interaction with NS2B/NS3 and blocks replication organelle formation

  • Nat Commun. 2024 Jul 19;15(1):6080. doi: 10.1038/s41467-024-50437-3.
Dominik Kiemel 1,  Ann-Sophie Helene Kroell 1,  Solène Denolly 1,  Uta Haselmann 1,  Jean-François Bonfanti 2 3,  Jose Ignacio Andres 4,  Brahma Ghosh 5,  Peggy Geluykens 6,  Suzanne J F Kaptein 7,  Lucas Wilken 8,  Pietro Scaturro 8,  Johan Neyts 7,  Marnix Van Loock 9,  Olivia Goethals 9,  Ralf Bartenschlager 10 11
Affiliations

Affiliations

  • 1 Heidelberg University, Medical Faculty Heidelberg, Department of Infectious Diseases, Molecular Virology, Center for Integrative Infectious Disease Research, Heidelberg, Germany.
  • 2 Janssen Infectious Diseases Discovery, Janssen-Cilag, Val de Reuil, France.
  • 3 Evotec, Toulouse, France.
  • 4 Discovery Chemistry, Janssen R&D, a Johnson & Johnson company, Toledo, Spain.
  • 5 Discovery Chemistry, Janssen R&D, a Johnson & Johnson company, Spring House, PA, USA.
  • 6 Discovery, Charles River Beerse, Beerse, Belgium.
  • 7 Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium.
  • 8 Leibniz Institute of Virology, Hamburg, Germany.
  • 9 Janssen Global Public Health, Janssen Pharmaceutica NV, a Johnson & Johnson company, Beerse, Belgium.
  • 10 Heidelberg University, Medical Faculty Heidelberg, Department of Infectious Diseases, Molecular Virology, Center for Integrative Infectious Disease Research, Heidelberg, Germany. ralf.bartenschlager@med.uni-heidelberg.de.
  • 11 German Centre for Infection Research, Heidelberg partner site, Heidelberg, Germany. ralf.bartenschlager@med.uni-heidelberg.de.
PMID: 39030239 DOI: 10.1038/s41467-024-50437-3
Abstract

Dengue fever represents a significant medical and socio-economic burden in (sub)tropical regions, yet antivirals for treatment or prophylaxis are lacking. JNJ-A07 was described as highly active against the different genotypes within each serotype of the disease-causing Dengue virus (DENV). Based on clustering of resistance mutations it has been assumed to target DENV non-structural protein 4B (NS4B). Using a photoaffinity labeling compound with high structural similarity to JNJ-A07, here we demonstrate binding to NS4B and its precursor NS4A-2K-NS4B. Consistently, we report recruitment of the compound to intracellular sites enriched for these proteins. We further specify the mechanism-of-action of JNJ-A07, which has virtually no effect on viral polyprotein cleavage, but targets the interaction between the NS2B/NS3 protease/helicase complex and the NS4A-2K-NS4B cleavage intermediate. This interaction is functionally linked to de novo formation of vesicle packets (VPs), the sites of DENV RNA replication. JNJ-A07 blocks VPs biogenesis with little effect on established ones. A similar mechanism-of-action was found for another NS4B inhibitor, NITD-688. In summary, we unravel the Antiviral mechanism of these NS4B-targeting molecules and show how DENV employs a short-lived cleavage intermediate to carry out an early step of the viral life cycle.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z